

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/000489-2022>

Tender

## **NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders including Haemophilia B**

The NHS Commissioning Board (operating under the name of NHS England)

F02: Contract notice

Notice identifier: 2022/S 000-000489

Procurement identifier (OCID): ocids-h6vhtk-030881

Published 7 January 2022, 1:22pm

### **Section I: Contracting authority**

#### **I.1) Name and addresses**

The NHS Commissioning Board (operating under the name of NHS England)

2nd Floor, Rutland House

Runcorn

WA7 2ES

#### **Contact**

Philip Grieve

#### **Email**

[philip.grieve@nhs.net](mailto:philip.grieve@nhs.net)

#### **Country**

United Kingdom

**NUTS code**

UK - United Kingdom

**Internet address(es)**

Main address

<https://www.england.nhs.uk/>

Buyer's address

<https://www.england.nhs.uk/>

**I.2) Information about joint procurement**

The contract is awarded by a central purchasing body

**I.3) Communication**

The procurement documents are available for unrestricted and full direct access, free of charge, at

<http://health.atamis.co.uk>

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

<http://health.atamis.co.uk>

Tenders or requests to participate must be submitted to the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

<http://health.atamis.co.uk>

**I.4) Type of the contracting authority**

Ministry or any other national or federal authority

**I.5) Main activity**

Health

---

## **Section II: Object**

### **II.1) Scope of the procurement**

#### **II.1.1) Title**

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders including Haemophilia B

Reference number

CM/PHS/19/5576

#### **II.1.2) Main CPV code**

- 33141530 - Blood coagulants

#### **II.1.3) Type of contract**

Supplies

#### **II.1.4) Short description**

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

#### **II.1.5) Estimated total value**

Value excluding VAT: £500,000,000

#### **II.1.6) Information about lots**

This contract is divided into lots: Yes

Tenders may be submitted for all lots

### **II.2) Description**

### **II.2.1) Title**

Lot 18 - Fresh Frozen Plasma

Lot No

18

### **II.2.2) Additional CPV code(s)**

- 33141530 - Blood coagulants

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

### **II.2.4) Description of the procurement**

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2022

End date

30 June 2024

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

Lot 16 - Prothrombin Complex dried

Lot No

16

### **II.2.2) Additional CPV code(s)**

- 33141530 - Blood coagulants

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

#### **II.2.4) Description of the procurement**

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

#### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

#### **II.2.6) Estimated value**

Value excluding VAT: £1

#### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2022

End date

30 June 2024

This contract is subject to renewal

No

#### **II.2.10) Information about variants**

Variants will be accepted: No

#### **II.2.11) Information about options**

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

Lot 15 - Fibrinogen Concentrate

Lot No

15

### **II.2.2) Additional CPV code(s)**

- 33141530 - Blood coagulants

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

### **II.2.4) Description of the procurement**

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2022

End date

30 June 2024

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

Lot 14 - Von willebrands factor - Recombinant

Lot No

14

### **II.2.2) Additional CPV code(s)**

- 33141530 - Blood coagulants

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

### **II.2.4) Description of the procurement**

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2022

End date

30 June 2024

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

Lot 17 - Protein C Concentrate

Lot No

17

### **II.2.2) Additional CPV code(s)**

- 33141530 - Blood coagulants

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

#### **II.2.4) Description of the procurement**

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

#### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

#### **II.2.6) Estimated value**

Value excluding VAT: £1

#### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2022

End date

30 June 2024

This contract is subject to renewal

No

#### **II.2.10) Information about variants**

Variants will be accepted: No

#### **II.2.11) Information about options**

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

Lot 10 - Factor XIII - Plasma Derived

Lot No

10

### **II.2.2) Additional CPV code(s)**

- 33141530 - Blood coagulants

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

### **II.2.4) Description of the procurement**

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2022

End date

30 June 2024

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

Lot 11 - Factor XIII - Recombinant

Lot No

11

**II.2.2) Additional CPV code(s)**

- 33141530 - Blood coagulants

**II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

**II.2.4) Description of the procurement**

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

**II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

**II.2.6) Estimated value**

Value excluding VAT: £1

**II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2022

End date

30 June 2024

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

Lot 9 - Factor X

Lot No

9

### **II.2.2) Additional CPV code(s)**

- 33141530 - Blood coagulants

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

#### **II.2.4) Description of the procurement**

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

#### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

#### **II.2.6) Estimated value**

Value excluding VAT: £1

#### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2022

End date

30 June 2024

This contract is subject to renewal

No

#### **II.2.10) Information about variants**

Variants will be accepted: No

#### **II.2.11) Information about options**

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

Lot 8 - Factor IX - High Purity Factor IX

Lot No

8

### **II.2.2) Additional CPV code(s)**

- 33141530 - Blood coagulants

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

### **II.2.4) Description of the procurement**

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2022

End date

30 June 2024

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

Lot 7 - Factor VIII Inhibitor Bypassing Fraction

Lot No

7

### **II.2.2) Additional CPV code(s)**

- 33141530 - Blood coagulants

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

### **II.2.4) Description of the procurement**

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2022

End date

30 June 2024

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

Lot 13 - Von willebrands factor - Plasma Derived

Lot No

13

### **II.2.2) Additional CPV code(s)**

- 33141530 - Blood coagulants

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

#### **II.2.4) Description of the procurement**

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

#### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

#### **II.2.6) Estimated value**

Value excluding VAT: £1

#### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2022

End date

30 June 2024

This contract is subject to renewal

No

#### **II.2.10) Information about variants**

Variants will be accepted: No

#### **II.2.11) Information about options**

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

Lot 12 - Factor VIII/ von willebrands factor

Lot No

12

### **II.2.2) Additional CPV code(s)**

- 33141530 - Blood coagulants

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

### **II.2.4) Description of the procurement**

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2022

End date

30 June 2024

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

Lot 6 - Porcine Factor VIII - susoctocog alfa

Lot No

6

### **II.2.2) Additional CPV code(s)**

- 33141530 - Blood coagulants

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

### **II.2.4) Description of the procurement**

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2022

End date

30 June 2024

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

Lot 5 - Recombinant Factor VII

Lot No

5

### **II.2.2) Additional CPV code(s)**

- 33141530 - Blood coagulants

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

#### **II.2.4) Description of the procurement**

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

#### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

#### **II.2.6) Estimated value**

Value excluding VAT: £1

#### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2022

End date

30 June 2024

This contract is subject to renewal

No

#### **II.2.10) Information about variants**

Variants will be accepted: No

#### **II.2.11) Information about options**

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

Lot 4 - rFIX - Standard Half Life

Lot No

4

### **II.2.2) Additional CPV code(s)**

- 33141530 - Blood coagulants

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

### **II.2.4) Description of the procurement**

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2022

End date

30 June 2024

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

Lot 3 - nonacog beta pegol (rFIX EHL)

Lot No

3

### **II.2.2) Additional CPV code(s)**

- 33141530 - Blood coagulants

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

### **II.2.4) Description of the procurement**

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £1

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2022

End date

30 June 2024

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

Lot 2 - albutrepenonacog alfa (rFIX EHL)

Lot No

2

### **II.2.2) Additional CPV code(s)**

- 33141530 - Blood coagulants

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

#### **II.2.4) Description of the procurement**

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

#### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

#### **II.2.6) Estimated value**

Value excluding VAT: £1

#### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2022

End date

30 June 2024

This contract is subject to renewal

No

#### **II.2.10) Information about variants**

Variants will be accepted: No

#### **II.2.11) Information about options**

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

Lot 1 - eftrenonacog alfa (rFIX EHL)

Lot No

1

### **II.2.2) Additional CPV code(s)**

- 33141530 - Blood coagulants

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above

### **II.2.4) Description of the procurement**

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

**II.2.6) Estimated value**

Value excluding VAT: £1

**II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

1 July 2022

End date

30 June 2024

This contract is subject to renewal

No

**II.2.10) Information about variants**

Variants will be accepted: No

**II.2.11) Information about options**

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

**II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

---

## **Section III. Legal, economic, financial and technical information**

### **III.1) Conditions for participation**

#### **III.1.2) Economic and financial standing**

Selection criteria as stated in the procurement documents

#### **III.1.3) Technical and professional ability**

Selection criteria as stated in the procurement documents

---

## **Section IV. Procedure**

### **IV.1) Description**

#### **IV.1.1) Type of procedure**

Open procedure

#### **IV.1.3) Information about a framework agreement or a dynamic purchasing system**

The procurement involves the establishment of a framework agreement

Framework agreement with several operators

#### **IV.1.8) Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: Yes

### **IV.2) Administrative information**

#### **IV.2.2) Time limit for receipt of tenders or requests to participate**

Date

14 February 2022

Local time

1:00pm

#### **IV.2.4) Languages in which tenders or requests to participate may be submitted**

English

**IV.2.6) Minimum time frame during which the tenderer must maintain the tender**

Tender must be valid until: 15 May 2022

**IV.2.7) Conditions for opening of tenders**

Date

14 February 2022

Local time

1:00pm

Place

Runcorn

Information about authorised persons and opening procedure

Commercial Medicines Unit Employee

---

**Section VI. Complementary information**

**VI.1) Information about recurrence**

This is a recurrent procurement: No

**VI.2) Information about electronic workflows**

Electronic ordering will be used

Electronic invoicing will be accepted

Electronic payment will be used

**VI.3) Additional information**

RESPONDING TO THIS NOTICE:

Any supplier may be disqualified who does not respond to the following in the requisite manner:

1) Submission of expression of interest and procurement specific information

This procurement exercise will be conducted on the eTendering portal at

<https://healthfamily.force.com/s/Welcome>

Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific

information (if requested) through the eTendering portal as follows:

1.1) If not already registered, Candidates should register on the eTendering portal at

<https://health-family.force.com/s/Welcome> and

click the link to register:

- agree to the user agreement

- populate company details

1.2) Once registered, candidates must register interest as follows:

- log to the portal

- select "Find Opportunities" from the supplier home screen, use the "Sort by:" facility to find this opportunity and select the bold blue title to select

- review opportunity details and click "Register Interest"

- as you select the opportunity, you can review documents, send clarification

- messages, submit the response or decline to respond (if

- you decide not to participate in the opportunity)

1.3) There is a supplier user guide on using the system and Candidates can contact the

Atamis help desk at [supporthealth@](mailto:supporthealth@atamis.co.uk)

[atamis.co.uk](mailto:supporthealth@atamis.co.uk) or by calling 0800 9956035 for technical assistance when

completing responses.

2) General supplier information.

To manage and assess supplier information the Contracting Authority requests

candidates provide their company profile in the Government's Supplier Registration

Service (which has replaced sid4gov), as follows:

2.1) If not already registered (the previous sid4gov password, login and details will still be on the system), candidates must go to the

following web page

<https://supplierregistration.cabinetoffice.gov.uk> and select "Register" at the top of the

page. Key in details as requested to search for your company. If you do not have a D-U-N-S® Number, click on the link at the right of the page to obtain a number from D&B.

Candidates must obtain a Dun & Bradstreet (D&B) D-U-N-S® Number to enable registration on the system.

2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed

and up to date for each procurement exercise.

D&B data will be supplied automatically by D&B.

2.3) For further help or information concerning this telephone +44 (0) 161 413 7982 or via the message function on the website.

**OTHER CONTRACTING AUTHORITIES**

The framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together

as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.

## **VI.4) Procedures for review**

### **VI.4.1) Review body**

The High Court

Strand

London

WC2A 2LL

Email

[generaloffice@administrativecourtoffice.justice.gov.uk](mailto:generaloffice@administrativecourtoffice.justice.gov.uk)

Country

United Kingdom

Internet address

<https://www.gov.uk/courts-tribunals>